Navigation Links
Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Date:10/17/2010

ime high, having increased 111 percent over a five-year period.(5)  

About NKTR-181 NKTR-181 is a novel mu-opioid analgesic investigational drug candidate created using Nektar's small molecule polymer conjugate technology.  In preclinical studies, NKTR-181 exhibits a reduced rate of entry into the central nervous system (CNS) providing effective pain relief with fewer CNS-related side effects, such as euphoria, sedation and respiratory depression.  The unique molecular design of the polymer conjugate also prevents conversion of NKTR-181 into free opioids or an abusable form of an opioid.  As a result, NKTR-181 has the potential to be a highly effective analgesic with a favorable safety profile and reduced potential for abuse, misuse and diversion.  

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas.  In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for Nektar's oral NKTR-118 development program to treat opioid-induced constipation and its NKTR-119 development program for the treatment of pain without constipation side effects.  The company has additional pain compounds in preclinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , Sept. 3,  2015 ... human-made bio-artificial devices, which are implanted or ... natural organs. These include artificial heart, kidney, ... as polymers (polyurethane, polysulfone, and porous polypropylene), ... develop artificial organs. These organs are incorporated ...
(Date:9/3/2015)... Sept. 3, 2015 About dry eye syndrome ... due to deficient tear production or quick tear evaporation ... two types: aqueous tear deficient dry eye and evaporative ... glands do not produce enough tears, whereas meibomian gland ... lipids to slow tear evaporation and maintain tear stability. ...
(Date:9/3/2015)... 2015  Ascendis Pharma A/S (Nasdaq: ... that applies its innovative TransCon technology to ... plans to present at several upcoming investor ... in BostonDate: , Thursday, September 10, 2015 Time: ... Merrill Lynch Global Healthcare Conference in LondonDate: ...
Breaking Medicine Technology:Global Artificial Organ Market 2015-2019 2Global Dry Eye Syndrome Market 2015-2019 2Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences 2
... , Ruling Opens Door to Physician Assisted ... Montana Supreme Court ruled that state law does not contain ... drugs to patients. This decision endangers the lives of the ... people,s lives, the law needs to draw a clear distinction ...
... For the twelfth consecutive year, Rev. Nicholas Hood, III, ... save lives during New Year,s Eve celebrations. Rev. Hood, ... Plan (HAP) and the Wayne County Sheriff,s Office, is asking ... without gunfire. The hope is that there will be ...
Cached Medicine Technology:Montana Supreme Court Decision Endangers Most Vulnerable Citizens 2Rev. Nick Hood, III Asks Southeast Michiganders Not to Use Guns During New Year's Eve Celebrations 2
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published September ... in nursing homes and assisted living facilities are receiving insufficient care that could actually ... her father was at one point close to death, not because of a medical ...
(Date:9/4/2015)... ... ... With TransCel from Pixel Film Studios users can simulate celluloid media transitions ... users have full control over camera position and angle within 3D space from start ... text, and more. With TransCel the possibilities are endless. , Users have full control ...
(Date:9/4/2015)... ... ... IVF New England, one of the largest and most successful fertility centers in ... women who wish to learn more about their fertility and egg freezing. , Date ... Street, Manchester, NH from 6PM to 7PM , This hip, casual and informative event ...
(Date:9/4/2015)... Monroe, NC (PRWEB) , ... September 04, 2015 ... ... Girl’s Night out to benefit Core Compassion Project. Core Compassion Project is ... a specialized program to reduce the side effects of cancer treatments and recover ...
(Date:9/4/2015)... ... September 04, 2015 , ... “Getting away from the daily ... to explore, revitalize and strengthen their ‘couple-ness,’” says Jean Claude Wietzel, general manager ... Seasons Resort Maui, the island’s only Forbes Five Star resort and Travel + Leisure’s ...
Breaking Medicine News(10 mins):Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3
... MA/Providence, RI -- Truck crashes are a significant ... injuries each year, with driver fatigue and sleepiness ... previous findings that obesity-driven testing strategies identify commercial ... sleep apnea (OSA) and suggests that mandating OSA ...
... On Friday, March 6, 2009, Coast IRB notified Criminal ... the FDA, and the Commonwealth of Virginia Department of Health ... discovered that a protocol submitted for review of a medical ... was fraudulent in violation of federal and state law. ...
... knowledge gap between the innovators who design medical devices and the ... hold intensive seminars on Materials and Processes for Medical Devices (MPMD). ... ... fill the knowledge gap between the innovators who design medical devices ...
... March 11 TeleHealth Services, the ... staff education and communications solutions, today announced a ... Meridian,s strategy to advance the hospital experience for ... patient experience, the New Jersey-based, not-for-profit health system ...
... an increased CO2 concentration exerted an influence on ... floating and mostly unicellular algae. The experiments were ... aerated with ordinary air or with air containing ... examined the ratio between the important elements carbon, ...
... will be the first product marketed under this arrangementMASON, ... today it has entered into a marketing and distribution ... FLONASE(R) (fluticasone propionate) Nasal Spray is the first product ... GSK,s agent and on GSK,s behalf, will solicit orders ...
Cached Medicine News:Health News:Obesity linked to dangerous sleep apnea in truck drivers 2Health News:Obesity linked to dangerous sleep apnea in truck drivers 3Health News:Clinical Trial Fraud Exposed by Coast IRB 2Health News:ASM Announces Seminars on Materials and Processes for Medical Devices 2Health News:TeleHealth Services and Meridian Health Partner to Create the Ultimate Patient Experience 2Health News:TeleHealth Services and Meridian Health Partner to Create the Ultimate Patient Experience 3Health News:TeleHealth Services and Meridian Health Partner to Create the Ultimate Patient Experience 4Health News:Prasco Selected as GSK's Generics Marketing and Distribution Agent 2
Slightly curved Periosteal elevator....
Coarse rasp....
Stainless steel bone clamp....
Cleveland Bone Cutter #5, 17cm, 6-3/4"...
Medicine Products: